血小板输注:2025年美国血库协会与国际输血医学指南协作组国际临床实践指南
该指南由美国血库协会(AABB)与国际输血医学指南协作组(ICTMG)制定,采用GRADE方法基于21项随机试验和13项观察性研究,针对成人与儿童常见血小板输注场景给出推荐。证据显示限制性输注策略相比宽松策略可能不增加死亡或出血,并针对不同临床情境给出了具体血小板计数阈值推荐。
要点
- 非出血性化疗或异基因干细胞移植后低增殖性血小板减少,血小板计数低于10×10³/μL时推荐输注(强推荐,高/中等确定性证据)。
- 无大出血的新生儿消耗性血小板减少,血小板计数低于25×10³/μL时推荐输注(强推荐,高/中等确定性证据)。
- 介入放射学操作:低风险操作血小板计数低于20×10³/μL、高风险操作低于50×10³/μL时推荐输注(条件推荐,低/极低确定性证据)。
核心结论
- 一致的证据模式支持实施限制性血小板输注策略,该策略可降低不良反应风险、缓解血小板短缺并降低成本;输注决策中考虑整体临床情况和替代疗法是良好实践。
研究设计与样本
- 该指南由美国血库协会(AABB)与国际输血医学指南协作组(ICTMG)制定,采用GRADE方法,基于21项随机试验和13项观察性研究,在随机临床试验数据有限的背景下比较限制性与宽松性血小板输注策略。
诊断标准与关键数值
- 非出血性接受化疗或异基因干细胞移植的低增殖性血小板减少患者,血小板计数低于10×10³/μL时推荐输注血小板(强推荐,高/中等确定性证据)。
- 无大出血的新生儿消耗性血小板减少,血小板计数低于25×10³/μL时推荐输注血小板(强推荐,高/中等确定性证据)。
- 接受腰椎穿刺的患者,血小板计数低于20×10³/μL时推荐输注血小板(强推荐,高/中等确定性证据)。
- 无大出血的登革热所致消耗性血小板减少患者,不推荐输注血小板(强推荐,高/中等确定性证据)。
- 接受自体干细胞移植或无再生障碍性贫血的非出血成人低增殖性血小板减少,不推荐预防性输注血小板(条件推荐,低/极低确定性证据);无大出血的成人消耗性血小板减少,血小板计数低于10×10³/μL时推荐输注(条件推荐,低/极低确定性证据);在可压迫解剖部位置入中心静脉导管的成人,血小板计数低于10×10³/μL时推荐输注(条件推荐,低/极低确定性证据);接受介入放射学操作的成人,低风险操作血小板计数低于20×10³/μL、高风险操作低于50×10³/μL时推荐输注(条件推荐,低/极低确定性证据);接受大型非神经轴手术的成人,血小板计数低于50×10³/μL时推荐输注(条件推荐,低/极低确定性证据);无重大出血且未接受体外循环的心血管手术患者(包括接受体外循环者)不推荐输注血小板(条件推荐,低/极低确定性证据);非手术性颅内出血且血小板计数大于100×10³/μL的成人(包括正在使用抗血小板药物者),不推荐输注血小板(条件推荐,低/极低确定性证据)。
临床应用与阅片要点
- 由于限制性策略定义在各试验间存在差异,推荐反映的是实用性指导。
- 输注决策中考虑整体临床情况和替代疗法是良好实践。
- 血小板减少患者接受腰椎穿刺时脊髓血肿发生率极低。
局限性
- 在随机临床试验数据有限的背景下应用GRADE方法。
- 由于限制性策略定义在各试验间存在差异,推荐反映的是实用性指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
IMPORTANCE: Platelet transfusion is a frequent procedure with benefits and risks.
OBJECTIVE: To provide recommendations in adult and pediatric populations in whom platelet transfusions are commonly performed.
EVIDENCE REVIEW: Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology was applied to findings from 21 randomized trials and 13 observational studies in contexts of limited randomized clinical trial data. Transfusion strategies using fewer (restrictive) vs greater (liberal) amounts of platelets were compared.
FINDINGS: Evidence demonstrated that restrictive transfusion strategies probably did not cause increases in mortality or bleeding relative to liberal strategies across predefined clinical populations. Exceedingly low incidence of spinal hematoma was identified in patients with thrombocytopenia undergoing lumbar puncture. Because definitions of restrictive strategies varied across trials, recommendations reflect practical guidance. The following recommendations are strong recommendations with high/moderate-certainty evidence. For hypoproliferative thrombocytopenia in nonbleeding patients receiving chemotherapy or undergoing allogeneic stem cell transplant, platelet transfusion is recommended when platelet count is less than 10 × 103/μL. For consumptive thrombocytopenia in neonates without major bleeding, platelet transfusion is recommended when platelet count is less than 25 × 103/μL. In patients undergoing lumbar puncture, platelet transfusion is recommended when platelet count is less than 20 × 103/μL. In patients with consumptive thrombocytopenia due to Dengue without major bleeding, platelet transfusion is not recommended. The following recommendations are conditional recommendations with low/very low-certainty evidence. For hypoproliferative thrombocytopenia in nonbleeding adults undergoing autologous stem cell transplant or with aplastic anemia, prophylactic platelet transfusion is not recommended. In adults with consumptive thrombocytopenia without major bleeding, platelet transfusion is recommended when platelet count is less than 10 × 103/μL. In adults undergoing central venous catheter placement in compressible anatomic sites, platelet transfusion is recommended when platelet count is less than 10 × 103/μL. In adults undergoing interventional radiology, platelet transfusion is recommended when platelet count is less than 20 × 103/μL for low-risk procedures and less than 50 × 103/μL for high-risk procedures. For adults undergoing major nonneuraxial surgery, platelet transfusion is recommended when platelet count is less than 50 × 103/μL. For patients without thrombocytopenia undergoing cardiovascular surgery in the absence of major hemorrhage, including those receiving cardiopulmonary bypass, platelet transfusion is not recommended. For nonoperative intracranial hemorrhage in adults with platelet count greater than 100 × 103/μL, including those receiving antiplatelet agents, platelet transfusion is not recommended.
CONCLUSIONS AND RELEVANCE: A consistent pattern of evidence supports the implementation of restrictive platelet transfusion strategies. Restrictive strategies reduce risk of adverse reactions, mitigate platelet shortages, and reduce costs. It is good practice to consider overall clinical context and alternative therapies in the decision to perform platelet transfusion.
引用
- Metcalf RA, Nahirniak S, Guyatt G, et al. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA. 2025. PMID: 40440268. doi:10.1001/jama.2025.7529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。